46
Participants
Start Date
April 30, 2005
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2010
Norditropin SimpleXx
0.3-0.4 mg/day placebo or GH for 4 weeks. Thereafter 0.6-0.8 mg/day placebo or GH for 11 months. During the following 24 months open phase doses will be individually titrated.
Center for rare Diseases, Department of Pediatrics, Skejby University Hospital, Aarhus N
Endokrinologisk seksjon, Med Avd, Rikshospitalet, Oslo
Department of Endocrinology and Diabetology, Karolinska Hospital, Stockholm
Collaborators (1)
Novo Nordisk A/S
INDUSTRY
Karolinska University Hospital
OTHER